ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call April 8, 2026 10:00 AM EDT
Company Participants
Sarah Kiely – Vice President of Investor Relations & Corporate Communications
Daniel de Boer – Founder, CEO & Executive Director
Cristina Lopez Lopez – Chief Medical Officer
Gerard Platenburg – Co-Founder, Chief Scientific Officer & Executive Director
Conference Call Participants
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Joe Thomas
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Catherine Novack – JonesTrading Institutional Services, LLC, Research Division
Suzanne van Voorthuizen – Kempen & Co. N.V., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Catherine Okoukoni – Citizens JMP Securities, LLC, Research Division
Kaey Nakae – Chardan Capital Markets, LLC, Research Division
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, and welcome to the ProQR Therapeutics Virtual Investor and Analyst Event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be made available on the ProQR website following the conclusion of the event. I’d now like to turn the call over to Sarah Kiely, Vice President of Investor Relations and Corporate Affairs. Please go ahead, Sarah.
Sarah Kiely
Vice President of Investor Relations & Corporate Communications
Thank you, and good day, everyone. We appreciate you taking the time to join us today. I’m Sarah Kiely, Vice President of Investor Relations and Corporate Affairs at ProQR. Before we begin, I’d like to briefly walk through today’s agenda and introduce our speakers.
We will start with opening remarks from our CEO, Daniel de Boer, who will provide an overview of our pipeline and recent advances. Following that, our Chief Medical Officer, Dr. Cristina Lopez Lopez, will discuss AX-0810, including a reminder of our ongoing Phase I healthy volunteer trial, expectations for the upcoming target engagement readout as well as an overview of our initial indication selection.
